Aditxt, Inc. (NASDAQ:ADTX – Get Free Report) major shareholder Paribas Securities Corp Bnp sold 20,800 shares of the company’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $33.23, for a total value of $691,184.00. Following the completion of the sale, the insider now owns 22,342 shares of the company’s stock, valued at $742,424.66. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Aditxt Price Performance
ADTX opened at $28.50 on Friday. Aditxt, Inc. has a 12 month low of $7.34 and a 12 month high of $1,139.60. The stock has a fifty day moving average price of $31.07 and a 200-day moving average price of $31.10.
Aditxt (NASDAQ:ADTX – Get Free Report) last released its quarterly earnings results on Monday, August 14th. The company reported ($36.80) EPS for the quarter, topping the consensus estimate of ($115.60) by $78.80. Aditxt had a negative return on equity of 777.58% and a negative net margin of 2,891.14%. The firm had revenue of $0.22 million during the quarter, compared to analyst estimates of $0.36 million. Analysts expect that Aditxt, Inc. will post -235.2 earnings per share for the current year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
Separately, HC Wainwright upped their target price on Aditxt to $61.00 and gave the stock a “buy” rating in a report on Wednesday.
Get Our Latest Analysis on ADTX
Aditxt Company Profile
Aditxt, Inc, a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues.
See Also
- Five stocks we like better than Aditxt
- What Is WallStreetBets and What Stocks Are They Targeting?
- The Best 5 Small Cap AI Companies to Buy Now
- Learn Technical Analysis Skills to Master the Stock Market
- Miso Robotics Stock: Is an IPO Coming Soon?
- How to Invest in Insurance Companies: A Guide
- 3 Stocks to Play the Easing Food Supply Chain
Receive News & Ratings for Aditxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aditxt and related companies with MarketBeat.com's FREE daily email newsletter.
